Protease inhibitor-induced urolithiasis

Urology

Volumn 50, Issue 4, 1997, Pages 508-511

  Gentle, Donald L ^b   Stoller, Marshall L ^a   Jarrett, Thomas W ^b   Ward, John F ^b   Geib, K Shane ^b   Wood, A Frederick ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; HEMATURIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KIDNEY COLIC; LITHOTRIPSY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; STONE FORMATION; URETER OBSTRUCTION; UROLITHIASIS;

ADULT; COLIC; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KIDNEY CALCULI; KIDNEY DISEASES; MALE; PROSPECTIVE STUDIES;

EID: 0030771285     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00401-9     Document Type: Article

References (7)

1. Becker K, Jablonowski H, and Haussinger D: Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Med 75: 185-194, 1996.
2. Indinavir sulfate (Crixivan®) (package insert). Merck & Co., West Point, Pennsylvania, March 1996.
3. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Drake PL, ZugayJ, Quintero JC, Blahy OH, Roth E, et al: L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 91: 4096-4100, 1994.
4. New drugs for HIV infection. Med Lett Drugs Ther 38: 35-37, 1996.
5. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, and Drusano GL: A 24-week open-label phase VII evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10: 485-492, 1996.
6. Gerberding JL: Prophylaxis for occupational exposure to HIV. Ann Intern Med 125: 497-501, 1996.
7. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 45: 468-480, 1996.